- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: ACP 103 | ACP-103 | Nuplazid (proposed trade name)
pimavanserin is an approved drug (FDA (2016))
Compound class: Synthetic organic
Comment: Pimavanserin is an inverse agonist of the serotonin 5-HT2A receptor . Pharmaceutical formulations contain pimavanserin tartrate (PubChem CID 67017013) .
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
View more information in the IUPHAR Pharmacology Education Project: pimavanserin
|No information available.|
|Summary of Clinical Use|
|In 2014 US FDA granted breakthrough therapy status for pimavanserin as a potential treatment for Parkinson's disease psychosis, following the completion of Phase 2I clinical trials for this indication. A Phase 2 trial administering pimavanserin as an adjunctive treatment for schizophrenia (in combination with antipsychotic medications such as risperidone and haloperidol) has also been completed. A further Phase 2 trial in patients with Alzheimer's disease psychosis is underway.
In November 2015, the US FDA confirmed that the New Drug Application (NDA) for Nuplazid® branded pimavanserin will be considered under it's 'Priority Review' process, to expedite its approval as a treatment of psychosis associated with Parkinson's disease, a condition for which there was no previous FDA-approved therapy. This Priority Review resulted in a 2016 approval for treating hallucinations and delusions associated with Parkinson's disease.